(TLRY) Tilray - Ratings and Ratios
Cannabis, Beverages, Wellness, Hemp, Pharmaceuticals
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 91.7% |
| Value at Risk 5%th | 111% |
| Relative Tail Risk | -26.30% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.24 |
| Alpha | -59.21 |
| CAGR/Max DD | -0.39 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.469 |
| Beta | 1.559 |
| Beta Downside | 2.076 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.25% |
| Mean DD | 50.82% |
| Median DD | 48.96% |
Description: TLRY Tilray December 01, 2025
Tilray Brands, Inc. (NASDAQ:TLRY) is a diversified lifestyle consumer-products company that cultivates, processes, and distributes medical and adult-use cannabis across North America, Europe, the Middle East, and Africa. It operates through four segments-Beverage, Cannabis, Distribution, and Wellness-selling a broad portfolio that includes proprietary cannabis brands (e.g., Tilray, Aphria, Broken Coast), hemp-based foods, alcoholic and non-alcoholic beverages, and related pharmaceutical and wellness products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, governments, and directly to consumers.
As of the latest Q3 2024 filing, Tilray reported revenue of $1.12 billion, up 18 % YoY, driven primarily by strong growth in its Beverage and Wellness segments, while its adjusted EBITDA margin remained negative at -12 % due to ongoing integration costs from recent acquisitions. The company’s cash position stood at $620 million, giving it roughly 12 months of runway at current burn rates. Key sector drivers include accelerating cannabis legalization in the United States (with 23 states now permitting adult-use sales) and a projected 10-12 % CAGR in global hemp-derived food products, both of which underpin Tilray’s expansion strategy.
For anyone looking to gauge Tilray’s longer-term upside, a deeper dive into its pipeline of branded beverage launches and the evolving regulatory landscape could be worthwhile.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-3.01b TTM) > 0 and > 6% of Revenue (6% = 69.6m TTM) |
| FCFTA -0.06 (>2.0%) and ΔFCFTA -3.83pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 37.39% (prev 52.96%; Δ -15.57pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.04 (>3.0%) and CFO -83.0m > Net Income -3.01b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (106.0m) change vs 12m ago 21.11% (target <= -2.0% for YES) |
| Gross Margin 28.68% (prev 29.42%; Δ -0.74pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 29.61% (prev 19.15%; Δ 10.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -82.98 (EBITDA TTM -2.96b / Interest Expense TTM 37.6m) >= 6 (WARN >= 3) |
Altman Z'' -20.71
| (A) 0.21 = (Total Current Assets 701.1m - Total Current Liabilities 267.6m) / Total Assets 2.08b |
| (B) -2.33 = Retained Earnings (Balance) -4.85b / Total Assets 2.08b |
| warn (B) unusual magnitude: -2.33 — check mapping/units |
| (C) -0.80 = EBIT TTM -3.12b / Avg Total Assets 3.92b |
| (D) -8.70 = Book Value of Equity -4.89b / Total Liabilities 562.0m |
| Total Rating: -20.71 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 47.74
| 1. Piotroski 1.0pt |
| 2. FCF Yield -11.86% |
| 3. FCF Margin -10.33% |
| 4. Debt/Equity 0.15 |
| 5. Debt/Ebitda 0.01 |
| 7. RoE -96.87% |
| 8. Rev. Trend 90.97% |
| 9. EPS Trend 26.08% |
What is the price of TLRY shares?
Over the past week, the price has changed by -6.07%, over one month by +26.81%, over three months by -46.92% and over the past year by -33.36%.
Is TLRY a buy, sell or hold?
- Strong Buy: 4
- Buy: 0
- Hold: 8
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TLRY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 16.2 | 77.1% |
| Analysts Target Price | 16.2 | 77.1% |
| ValueRay Target Price | 6.4 | -29.5% |
TLRY Fundamental Data Overview January 09, 2026
P/S = 1.2553
P/B = 0.6972
Beta = 2.115
Revenue TTM = 1.16b USD
EBIT TTM = -3.12b USD
EBITDA TTM = -2.96b USD
Long Term Debt = 228.4m USD (from longTermDebt, last quarter)
Short Term Debt = 23.8m USD (from shortTermDebt, last quarter)
Debt = 231.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -33.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.01b USD (1.04b + Debt 231.3m - CCE 264.8m)
Interest Coverage Ratio = -82.98 (Ebit TTM -3.12b / Interest Expense TTM 37.6m)
FCF Yield = -11.86% (FCF TTM -119.7m / Enterprise Value 1.01b)
FCF Margin = -10.33% (FCF TTM -119.7m / Revenue TTM 1.16b)
Net Margin = -259.3% (Net Income TTM -3.01b / Revenue TTM 1.16b)
Gross Margin = 28.68% ((Revenue TTM 1.16b - Cost of Revenue TTM 826.8m) / Revenue TTM)
Gross Margin QoQ = 27.43% (prev 30.12%)
Tobins Q-Ratio = 0.48 (Enterprise Value 1.01b / Total Assets 2.08b)
Interest Expense / Debt = 3.98% (Interest Expense 9.20m / Debt 231.3m)
Taxrate = 5.26% (-166.1m / -3.16b)
NOPAT = -2.96b (EBIT -3.12b * (1 - 5.26%)) [loss with tax shield]
Current Ratio = 2.62 (Total Current Assets 701.1m / Total Current Liabilities 267.6m)
Debt / Equity = 0.15 (Debt 231.3m / totalStockholderEquity, last quarter 1.54b)
Debt / EBITDA = 0.01 (negative EBITDA) (Net Debt -33.5m / EBITDA -2.96b)
Debt / FCF = 0.28 (negative FCF - burning cash) (Net Debt -33.5m / FCF TTM -119.7m)
Total Stockholder Equity = 3.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -76.78% (Net Income -3.01b / Total Assets 2.08b)
RoE = -96.87% (Net Income TTM -3.01b / Total Stockholder Equity 3.10b)
RoCE = -93.64% (EBIT -3.12b / Capital Employed (Equity 3.10b + L.T.Debt 228.4m))
RoIC = -114.3% (out of range, set to none) (NOPAT -2.96b / Invested Capital 2.59b)
WACC = 10.31% (E(1.04b)/V(1.27b) * Re(11.76%) + D(231.3m)/V(1.27b) * Rd(3.98%) * (1-Tc(0.05)))
Discount Rate = 11.76% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 20.45%
Fair Price DCF = unknown (Cash Flow -119.7m)
EPS Correlation: 26.08 | EPS CAGR: -1.22% | SUE: 0.06 | # QB: 0
Revenue Correlation: 90.97 | Revenue CAGR: 10.40% | SUE: 0.71 | # QB: 0
EPS next Quarter (2026-02-28): EPS=0.10 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-05-31): EPS=0.02 | Chg30d=+0.231 | Revisions Net=+0 | Growth EPS=-78.1% | Growth Revenue=+5.1%
EPS next Year (2027-05-31): EPS=-0.27 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+31.1% | Growth Revenue=+4.4%
Additional Sources for TLRY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle